Search - tctmd.com

Displaying 21 - 40 of 128

Sort: Relevancy | Date

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

Shelley Wood

April 01, 2024

News Daily News

Real-life Patients Do Well With Intravascular Lithotripsy: Spanish Registry

Caitlin E. Cox

March 01, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Features

A Sham-Controlled Trial of AF Ablation Is Feasible, but Is It Needed?

Todd Neale

January 25, 2024

News Opinion Editor's Corner

The Biggest News of 2023: TCTMD’s Top 10

Shelley Wood

January 01, 2024

News Daily News

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

Michael O'Riordan

December 27, 2023

News Daily News

Top Coronary Artery Disease News of 2023

Michael O'Riordan

December 22, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2023

Shelley Wood

November 30, 2023

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Daily News

Sham Procedures in CV Research: What’s Sacrificed for Science?

Caitlin E. Cox

October 23, 2023

News Daily News

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

Todd Neale

October 16, 2023

News Conference News EuroPCR 2023

Meta-analysis Finds No Excess Mortality Risk With Coronary Revascularization

Michael O'Riordan

May 19, 2023

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Daily News

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Michael O'Riordan

September 15, 2022

News Daily News

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

Michael O'Riordan

January 25, 2022

News Daily News

ORBITA Data Undercut the Idea PCI Does Best in Focal CAD

Caitlin E. Cox

August 06, 2021

News Conference News EuroPCR 2021

Elective Revascularization, Better Long-term Survival: Meta-analysis

Michael O'Riordan

May 18, 2021

News Daily News

Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles

Michael O'Riordan

May 12, 2021

News Daily News

FDA Approves Shockwave Intravascular Lithotripsy for Calcified Coronaries

Shelley Wood

February 16, 2021

Advertisement

What’s Going to Be Hot at ACC 2024

Real-life Patients Do Well With Intravascular Lithotripsy: Spanish Registry

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

A Sham-Controlled Trial of AF Ablation Is Feasible, but Is It Needed?

The Biggest News of 2023: TCTMD’s Top 10

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

Top Coronary Artery Disease News of 2023

TCTMD’s Top 10 Most Popular Stories for November 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

What’s Going to Be Hot at AHA 2023

Sham Procedures in CV Research: What’s Sacrificed for Science?

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

Meta-analysis Finds No Excess Mortality Risk With Coronary Revascularization

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

ORBITA Data Undercut the Idea PCI Does Best in Focal CAD

Elective Revascularization, Better Long-term Survival: Meta-analysis

Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles

FDA Approves Shockwave Intravascular Lithotripsy for Calcified Coronaries

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content